BeOne Medicines AG (SHA:688235)
289.45
-9.35 (-3.13%)
Nov 17, 2025, 2:14 PM CST
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of 1.44B CNY in the quarter ending September 30, 2025, with 37.85% growth. This brings the company's revenue in the last twelve months to 5.00B, up 49.15% year-over-year. In the year 2024, BeOne Medicines AG had annual revenue of 3.81B with 54.96% growth.
Revenue (ttm)
5.00B
Revenue Growth
+49.15%
P/S Ratio
8.08
Revenue / Employee
3.24M
Employees
11,000
Market Cap
287.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| WuXi AppTec | 43.88B |
| Huadong Medicine | 43.09B |
| Yunnan Baiyao Group Co.,Ltd | 40.77B |
| Shanghai Fosun Pharmaceutical (Group) | 39.55B |
| Shenzhen Mindray Bio-Medical Electronics | 33.07B |
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 30.98B |
| Zhejiang NHU Company | 22.47B |
| Aier Eye Hospital Group | 22.17B |
BeOne Medicines AG News
- 10 days ago - BeiGene Non-GAAP EPADS of $2.65, revenue of $1.4B beats by $40M - Seeking Alpha
- 11 days ago - BeiGene Q3 2025 Earnings Preview - Seeking Alpha
- 2 months ago - BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up - Benzinga
- 3 months ago - A Glimpse of BeiGene's Earnings Potential - Benzinga
- 3 months ago - BeiGene's Earnings: A Preview - Benzinga
- 3 months ago - BeiGene Q2 2025 Earnings Preview - Seeking Alpha
- 5 months ago - Glenmark Pharmaceuticals launches TEVIMBRA in India for advanced lung and esophageal cancer treatment - Business Upturn
- 5 months ago - Glenmark Pharmaceuticals to launch Zanubrutinib (BRUKINSA) in India after DCGI approval - Business Upturn